{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:32:10Z","timestamp":1791469930757,"version":"4.3.4"},"reference-count":64,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jchf.2025.102610","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T01:00:28Z","timestamp":1758070828000},"page":"102610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Frailty and Effects of Semaglutide in Obesity-Related HFpEF"],"prefix":"10.1016","volume":"13","author":[{"given":"Ambarish","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalane W.","family":"Kitzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaja M.","family":"Chinnakondepalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shachi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A.","family":"Borlaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5655-8201","authenticated-orcid":false,"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-8533","authenticated-orcid":false,"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"R\u00f6nnb\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Domdey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Liisberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fozia Z.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2025.102610_bib1","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102610_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2025.102610_bib3","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jacc.2021.07.014","article-title":"Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC state-of-the-art review","volume":"78","author":"Pandey","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102610_bib4","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.jacc.2018.02.059","article-title":"Domain management approach to heart failure in the geriatric patient: present and future","volume":"71","author":"Gorodeski","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102610_bib5","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1111\/jgs.15141","article-title":"Evolution of geriatric syndrome: pathophysiology and treatment of heart failure with preserved ejection fraction","volume":"65","author":"Upadhya","year":"2017","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jchf.2025.102610_bib6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jacc.2023.05.038","article-title":"Impact of geroscience on therapeutic strategies for older adults with cardiovascular disease: JACC scientific statement","volume":"82","author":"Forman","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102610_bib7","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jchf.2019.10.005","article-title":"Frailty is intertwined with heart failure: mechanisms, prevalence, prognosis, assessment, and management","volume":"7","author":"Pandey","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2025.102610_bib8","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/jcsm.13306","article-title":"Frailty and heart failure: state-of-the-art review","volume":"14","author":"Talha","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jchf.2025.102610_bib9","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/CIRCULATIONAHA.122.061754","article-title":"Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial","volume":"146","author":"Butt","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2025.102610_bib10","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jacc.2022.06.037","article-title":"Sacubitril\/valsartan and frailty in patients with heart failure and preserved ejection fraction","volume":"80","author":"Butt","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102610_bib11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/jcsm.13393","article-title":"Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved","volume":"15","author":"Coats","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jchf.2025.102610_bib12","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/ejhf.1611","article-title":"Heart Failure Association\/European Society of Cardiology position paper on frailty in patients with heart failure","volume":"21","author":"Vitale","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2025.102610_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102610_bib14","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1177\/2047487319835042","article-title":"Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction","volume":"26","author":"Veenis","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jchf.2025.102610_bib15","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jchf.2021.12.004","article-title":"Frailty, guideline-directed medical therapy, and outcomes in HFrEF: from the GUIDE-IT trial","volume":"10","author":"Khan","year":"2022","journal-title":"JACC Heart Failure"},{"key":"10.1016\/j.jchf.2025.102610_bib16","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2025.102610_bib17","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2025.102610_bib18","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2025.102610_bib19","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets","volume":"118","author":"Borlaug","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jchf.2025.102610_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2025.102610_bib21","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.mayocp.2023.07.008","article-title":"Obesity, cardiorenal comorbidities, and risk of hospitalization in patients with heart failure with preserved ejection fraction","volume":"98","author":"Morgen","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jchf.2025.102610_bib22","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jchf.2018.08.007","article-title":"Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic\/obese HFpEF","volume":"6","author":"Kitzman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2025.102610_bib23","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCHEARTFAILURE.110.959890","article-title":"Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial","volume":"4","author":"Haass","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2025.102610_bib24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/21551197.2019.1572570","article-title":"Long-term effects of randomization to a weight loss intervention in older adults: a pilot study","volume":"38","author":"Houston","year":"2019","journal-title":"J Nutr Gerontol Geriatr"},{"key":"10.1016\/j.jchf.2025.102610_bib25","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2025.102610_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.16775","article-title":"Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial","volume":"7","author":"Jensen","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jchf.2025.102610_bib27","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/jcsm.13445","article-title":"Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: results from a randomized clinical trial","volume":"15","author":"Pandey","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jchf.2025.102610_bib28","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004281","article-title":"Making the case for skeletal muscle myopathy and its contribution to exercise intolerance in heart failure with preserved ejection fraction","volume":"10","author":"Kitzman","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2025.102610_bib29","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.amjcard.2013.12.031","article-title":"Skeletal muscle composition and its relation to exercise intolerance in older patients with heart failure and preserved ejection fraction","volume":"113","author":"Haykowsky","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2025.102610_bib30","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamacardio.2023.0957","article-title":"Skeletal muscle mitochondrial respiration and exercise intolerance in patients with heart failure with preserved ejection fraction","volume":"8","author":"Scandalis","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2025.102610_bib31","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jchf.2023.05.010","article-title":"Design and baseline characteristics of STEP-HFpEF program evaluating semaglutide in patients with obesity HFpEF phenotype","volume":"11","author":"Kosiborod","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2025.102610_bib32","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/gerona\/62.7.722","article-title":"Frailty in relation to the accumulation of deficits","volume":"62","author":"Rockwood","year":"2007","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jchf.2025.102610_bib33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1100\/tsw.2001.58","article-title":"Accumulation of deficits as a proxy measure of aging","volume":"1","author":"Mitnitski","year":"2001","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.jchf.2025.102610_bib34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2318-8-24","article-title":"A standard procedure for creating a frailty index","volume":"8","author":"Searle","year":"2008","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.jchf.2025.102610_bib35","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/jgs.12420","article-title":"Operationalization of frailty using eight commonly used scales and comparison of their ability to predict all-cause mortality","volume":"61","author":"Theou","year":"2013","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jchf.2025.102610_bib36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11357-017-9993-7","article-title":"A frailty index from common clinical and laboratory tests predicts increased risk of death across the life course","volume":"39","author":"Blodgett","year":"2017","journal-title":"Geroscience"},{"key":"10.1016\/j.jchf.2025.102610_bib37","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.archger.2015.01.016","article-title":"Frailty in NHANES: comparing the frailty index and phenotype","volume":"60","author":"Blodgett","year":"2015","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.jchf.2025.102610_bib38","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40520-018-1023-9","article-title":"Application of an electronic frailty index in Australian primary care: data quality and feasibility assessment","volume":"31","author":"Ambagtsheer","year":"2019","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.jchf.2025.102610_bib39","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/gerona\/glad088","article-title":"Long-term impact of a 10-year intensive lifestyle intervention on a deficit accumulation frailty index: Action for Health in Diabetes trial","volume":"78","author":"Evans","year":"2023","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jchf.2025.102610_bib40","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/ejhf.1308","article-title":"The frailty syndrome and outcomes in the TOPCAT trial","volume":"20","author":"Sanders","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2025.102610_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afac309","article-title":"The frailty index based on laboratory test data as a tool to investigate the impact of frailty on health outcomes: a systematic review and meta-analysis","volume":"52","author":"Sapp","year":"2023","journal-title":"Age Ageing"},{"key":"10.1016\/j.jchf.2025.102610_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afad221","article-title":"How to construct a frailty index from an existing dataset in 10 steps","volume":"52","author":"Theou","year":"2023","journal-title":"Age Ageing"},{"key":"10.1016\/j.jchf.2025.102610_bib43","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/ejhf.3221","article-title":"Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: principal findings and meta-analysis with the DELIVER trial","volume":"26","author":"Sattar","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2025.102610_bib44","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","article-title":"Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial","volume":"29","author":"Borlaug","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jchf.2025.102610_bib45","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cmet.2023.08.003","article-title":"A big STEP for treatment of heart failure with preserved ejection fraction","volume":"35","author":"Verma","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.jchf.2025.102610_bib46","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1161\/HYPERTENSIONAHA.124.24214","article-title":"Impact of frailty on antihypertensive treatment in older adults","volume":"82","author":"Chen","year":"2025","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2025.102610_bib47","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/ejhf.1832","article-title":"The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE","volume":"22","author":"Dewan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2025.102610_bib48","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/jamacardio.2022.4903","article-title":"Frailty and effects of a multidomain physical rehabilitation intervention among older patients hospitalized for acute heart failure: a secondary analysis of a randomized clinical trial","volume":"8","author":"Pandey","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2025.102610_bib49","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.122.059983","article-title":"Frailty status modifies the efficacy of exercise training among patients with chronic heart failure and reduced ejection fraction: an analysis from the HF-ACTION trial","volume":"146","author":"Pandey","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2025.102610_bib50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2024.04.022","article-title":"Semaglutide and NT-proBNP in obesity-related HFpEF: insights from the STEP-HFpEF program","volume":"84","author":"Petrie","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102610_bib51","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jacc.2024.04.038","article-title":"Semaglutide and NYHA functional class in obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF program","volume":"84","author":"Schou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102610_bib52","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1093\/eurheartj\/ehae322","article-title":"Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials","volume":"45","author":"Shah","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2025.102610_bib53","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jchf.2025.102610_bib54","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Muller","year":"2019","journal-title":"Mol Metab"},{"key":"10.1016\/j.jchf.2025.102610_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2022.119300","article-title":"GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R\/AMPK pathway","volume":"1869","author":"Wu","year":"2022","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.1016\/j.jchf.2025.102610_bib56","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13202","article-title":"Glucagon-like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle","volume":"19","author":"Abdulla","year":"2020","journal-title":"Aging Cell"},{"key":"10.1016\/j.jchf.2025.102610_bib57","doi-asserted-by":"crossref","first-page":"9446","DOI":"10.1038\/s41598-023-36602-6","article-title":"GLP-1 receptor agonist protects palmitate-induced insulin resistance in skeletal muscle cells by up-regulating sestrin2 to promote autophagy","volume":"13","author":"Tian","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jchf.2025.102610_bib58","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2025.102610_bib59","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2025.102610_bib60","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3803\/EnM.2019.34.3.247","article-title":"A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans","volume":"34","author":"Sargeant","year":"2019","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.jchf.2025.102610_bib61","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/nutrit\/nuv065","article-title":"Effects of dietary protein intake on body composition changes after weight loss in older adults: a systematic review and meta-analysis","volume":"74","author":"Kim","year":"2016","journal-title":"Nutr Rev"},{"key":"10.1016\/j.jchf.2025.102610_bib62","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00125-019-05065-8","article-title":"Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial","volume":"63","author":"McCrimmon","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.jchf.2025.102610_bib63","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dci23-0100","article-title":"Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition?","volume":"47","author":"Locatelli","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jchf.2025.102610_bib64","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jchf.2023.06.009","article-title":"Frailty status modifies the efficacy of ICD therapy for primary prevention among patients with HF","volume":"12","author":"Segar","year":"2024","journal-title":"JACC Heart Fail"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925005384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925005384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:39:42Z","timestamp":1760074782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177925005384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2213177925005384"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2025.102610","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frailty and Effects of Semaglutide in Obesity-Related HFpEF","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2025.102610","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102610"}}